169447-74-9

Upstream product

• 6404-28-0 Boc-Nle-OH 
• 6436-90-4 ethyl 2-(benzylamino)acetate 

Downstream Products

• 175357-61-6 (S)-1-Benzyl-3-butyl-piperazine 
• 169447-75-0 4-Benzyl-1-tert-butoxycarbonyl-2(S)-n-butylpiperazine 
• 169448-30-0 {(R)-1-[(S)-2-Butyl-4-(naphthalene-1-carbonyl)-piperazin-1-ylmethyl]-2-tritylsulfanyl-ethyl}-carbamic acid tert-butyl ester 
• 169447-77-2 {(R)-1-[(S)-2-Butyl-4-(2,3-dimethyl-benzoyl)-piperazin-1-ylmethyl]-2-tritylsulfanyl-ethyl}-carbamic acid tert-butyl ester 
• 169447-78-3 1-tert-butoxycarbonyl-2(S)-n-butyl-4-(2,3-dimethylbenzoyl)piperazine 
• 205679-66-9 ((S)-3-Butyl-piperazin-1-yl)-(2,3-dimethyl-phenyl)-methanone 
• 169447-76-1 1-tert-butoxycarbonyl-2(S)-n-butylpiperazine 

Relevant academic research and scientific papers

17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of

17-Beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

There are disclosed compounds of the formula (I): prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.